Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients.
نویسندگان
چکیده
Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients We read with interest the study by Zhang et al. [1] on the association between the LCS6 T/G variant (rs61764370) and
منابع مشابه
A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
PURPOSE Colorectal cancer (CRC) is a common cause of death worldwide. Tumor-node-metastasis-system stage is currently used to guide therapy decisions but lacks precision. Prognostic biomarkers are needed to refine stratification of patients for chemotherapy but validated biomarkers are not yet available. Recently, a SNP in a lethal-7 (let-7) miRNA complementary site (LCS6) in the KRAS 3'untrans...
متن کاملP-244: Analysis of Genomic and Cell Free DNA of A let-7 microRNA Binding Site of KRAS Gene Polymorphisms in Endometriosis
Background: Endometriosis is one of the most common benign gynecological diseases which is characterized by endometriallike tissue growing outside the uterine cavity. Although the pathology of endometriosis remains unknown, the genetic predisposition plays an apparent role. Several genes have been contributed to endometriosis, but it seems KRAS has a crucial role, because its activation results...
متن کاملLet-7 microRNA-binding-site polymorphism in the 3′UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis
There is a small but growing body of literature regarding the predictive utility of a Let-7 microRNA-binding-site polymorphism in the 3'-untranslated region (UTR) of KRAS (KRAS-LCS6) for colorectal cancer outcome, although the results are conflicting. We performed a review and meta-analysis in an attempt to better clarify this relationship. A PubMed search was conducted to identify all studies ...
متن کاملارزیابی فراوانی جهش‌های ژن KRAS در بیماران ایرانی مبتلا به سرطان کولورکتال
Background: Kirsten rat sarcoma (KRAS) gene is a target of genetic alterations which are diagnostic and prognostic biomarkers in patients with metastatic colorectal cancer who are treated with monoclonal anti-EGFR antibodies such as cetuximab and panitumumab. KRAS mutations are seen in 35-42% of patients with colorectal cancer. The high frequency of these mutations in colorectal cancer represen...
متن کاملAssociation study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
PURPOSE A let-7 microRNA-complementary site (LCS6) polymorphism in the 3' untranslated region of the KRAS gene has been shown to disrupt let-7 binding and upregulate KRAS expression. We evaluated the LCS6 genotype and its association with KRAS mutation status, clinicopathologic features, and disease-free survival (DFS) in patients with stage III colon cancer who enrolled in a phase III clinical...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Annals of oncology : official journal of the European Society for Medical Oncology
دوره 22 1 شماره
صفحات -
تاریخ انتشار 2011